MONTE ROSA THERAPEUTICS INC (GLUE) Stock Income Statement
NASDAQ:GLUE - Nasdaq - US61225M1027 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 75.62M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 156.73M | 143.31M | 112.38M | 72.88M | 28.01M | |||
| Research and Development | 112.86M | 103.37M | 77.26M | 57.16M | 24.01M | |||
| Selling, General, and Administrative Expenses | 43.87M | 39.94M | 35.12M | 15.73M | 4.01M | |||
| Operating Income | -81.11M | -143.31M | -112.38M | -72.88M | -28.01M | |||
| Interest Income/Expense | 10.98M | 8.27M | 3.77M | -120.00K | -190.00K | |||
| Other Income/Expense | N/A | N/A | 0.00 | -960.00K | -7.68M | |||
| Income Before Taxes | -70.13M | -135.01M | -108.50M | -73.96M | -35.88M | |||
| Income Tax | 2.57M | 338.00K | N/A | N/A | N/A | |||
| Net Income | -72.70M | -135.35M | -108.50M | -73.96M | -35.88M | |||
| EBITDA | -72.99M | -137.09M | -108.63M | -70.75M | -27.47M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.98 | -2.63 | -2.30 | -1.59 | -0.81 | |||
| Non GAAP EPS | -1.02 | -2.64 | -2.29 | N/A | N/A | |||
| Statistics | ||||||||
| Profit Margin | -96.14% | N/A | N/A | N/A | N/A | |||
| Operating Profit Margin | -107.26% | N/A | N/A | N/A | N/A | |||
All data in USD